SLV 322Alternative Names: SLV322
Latest Information Update: 18 Jul 2007
At a glance
- Originator Solvay
- Class Antiarrhythmics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 06 May 2005 This compound is still in active development
- 26 Aug 2003 Preclinical trials in Arrhythmias in USA (unspecified route)